Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

PURPOSE: Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in g...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Sampson, John H., Heimberger, Amy B., Archer, Gary E., Aldape, Kenneth D., Friedman, Allan H., Friedman, Henry S., Gilbert, Mark R., Herndon, James E., McLendon, Roger E., Mitchell, Duane A., Reardon, David A., Sawaya, Raymond, Schmittling, Robert J., Shi, Weiming, Vredenburgh, James J., Bigner, Darell D.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3020702/
https://ncbi.nlm.nih.gov/pubmed/20921459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.28.6963
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares